Dossier · Private startup · 2 independent sources
Remilk
Last updated: Jul 31, 2026
Remilk is an Israeli food-technology startup that uses engineered yeast and precision fermentation to produce animal-free dairy proteins for milk and other dairy applications. Its 2025 launch with Gad Dairies provides a concrete commercialization signal, while the company remains exposed to the difficult economics of scaling food-grade fermentation.
Visit WebsiteCompany Overview
Remilk develops dairy proteins without cows. According to its science materials, the company inserts a gene associated with a cow milk protein into yeast, grows the organism in fermentors, and then processes the resulting protein into an ingredient that can be combined with non-animal fats, sugars, vitamins, and minerals. The proposition is different from a plant-based substitute: the company is trying to reproduce the functional building blocks of dairy, including the behavior required for foaming, cooking, emulsification, and familiar taste and texture. The product is therefore best understood as a recombinant-protein and formulation platform, not simply as a branded milk alternative.
The initial customer logic is business-to-business. Remilk can supply an ingredient for beverages, barista products, ice cream, yogurt, cream cheese, and other formulations, while dairy and food manufacturers contribute processing, distribution, regulatory experience, and consumer brands. Remilk and Gad Dairies launched The New Milk in Israel in late 2025, with food-service products followed by planned retail products. That is meaningful evidence of product integration and market readiness, but it does not by itself establish repeatable high-volume economics, broad consumer retention, or international scale. Public reporting also describes regulatory clearances in Israel, the United States, Singapore, and Canada; the exact scope, labeling conditions, and commercial status of each market should remain diligence items.
The competitive field is crowded and includes other precision-fermentation companies such as Imagindairy, Perfect Day, Vivici, and Formo, as well as plant-based proteins and conventional dairy. Remilk claims a sensory and functional advantage over many plant alternatives because its target proteins are structurally similar to animal-derived dairy proteins. Its practical edge will depend less on the claim itself than on yield, titer, purification cost, formulation performance, allergen and labeling treatment, and the ability to secure manufacturing capacity. The 2022 Series B and the company-reported investment base show that investors have funded substantial development, but financing history is not proof that the business has reached cost parity or positive operating margins.
Remilk has moved from laboratory development toward commercialization, so mature is appropriate as an operating stage within a private startup database. The Gad relationship gives it an established route to market in Israel, and the company has described United States expansion discussions. There are also earlier signals of ingredient use in animal-free cream cheese and of planned large-scale fermentation capacity. Those signals should be separated from execution: announced facilities, partner plans, and product launches can still face construction, qualification, working-capital, and demand risks. The key commercial question is whether Remilk can turn a technically differentiated protein into a dependable ingredient supply business across multiple geographies and product categories.
The national-security relevance is indirect but credible. Remilk is not a defense contractor, sensor company, or military supplier, and there is no public evidence of defense contracts or operational defense use. Its relevance comes from food-system resilience: precision fermentation can reduce dependence on herds, feed, agricultural land, water availability, and climate-sensitive production, while potentially allowing protein manufacturing closer to strategic markets. That could support contingency nutrition and civil-resilience planning, but the security case is conditional on affordable inputs, reliable electricity and water, bioprocess capacity, regulatory acceptance, and the ability to maintain production during disruption. The strongest diligence questions are scale economics, actual output and margins, regulatory scope, partner concentration, and whether claimed resource advantages persist once downstream processing and full system boundaries are included.
Dual-Use Assessment
Remilk has no public defense product or military customer. Its core precision-fermentation capability nevertheless has substantive civil-security applicability because it can produce dairy proteins with less dependence on livestock, imported feed, agricultural land, and climate-sensitive supply chains. The dual-use case is food and infrastructure resilience rather than battlefield technology, and depends on demonstrated cost, capacity, shelf stability, and continuity under disruption.
Strategic Fit Assessment
Priority signal means this entry may be worth researching within the Claw & Talon thesis. It does not mean investable, suitable, endorsed, available, or likely to produce returns.
Remilk is a credible internal priority signal for a deep-tech and resilience thesis because it combines a technically demanding biomanufacturing platform with a large food market and an observable commercial launch. The case is strategic diligence, not an investment recommendation: the principal unresolved questions are fermentation yield, downstream cost, available capacity, cash requirements, regulatory breadth, partner dependence, and repeat purchase behavior. Its indirect security value improves the thesis but does not compensate for weak unit economics or execution risk.
Strategic Value to U.S.-Israel Alliance
Remilk could add resilience to the dairy-protein supply chain by shifting part of production from herds and feed systems to controlled fermentation. That may matter for countries facing water stress, climate volatility, import exposure, or emergency nutrition requirements. The strategic value is strongest as industrial biotechnology and food-security infrastructure, with possible civil-resilience applications; it should not be described as a defense capability absent public evidence of defense customers or contracts.
Key Technologies
- Engineered yeast for recombinant dairy-protein expression
- Precision-fermentation process development and scale-up
- Food-grade protein recovery and drying
- Dairy-protein formulation with non-animal fats, sugars, vitamins, and minerals
- Functional performance testing for foaming, emulsification, heat stability, and texture
- Regulatory and quality systems for animal-free food ingredients
Use Cases & Applications
- Animal-free milk and fortified milk beverages
- Barista milk for cafes, restaurants, and hotels
- Cream cheese and other spreadable dairy formulations
- Ice cream and frozen-dessert formulations
- Yogurt and cultured-dairy style products
- Ingredient supply for food manufacturers seeking dairy functionality without livestock
- Contingency nutrition and food-system resilience where livestock supply is disrupted
Sources and verification
This profile is based on public-source research, Claw & Talon curation, and editorial judgment. Inclusion does not imply endorsement, partnership, investment, or a recommendation to transact. Readers should still confirm current status, customers, funding, and product claims before relying on this profile. The editorial policy explains how profiles are researched, where automated drafting is used, and how corrections work; the research methodology documents how evidence is graded, what counts as an independent source, and why some profiles are excluded from search indexing.
This record lists 7 public references used for company identity, status, positioning, or material-claim review.
Public sources
The links below are visible public references used for source discipline around company identity, status, funding, customer, acquisition, public-company, or other material claims where available.
- Remilk official homepage Official company website and mission positioning.
- Remilk science page Official explanation of engineered yeast, fermentors, dairy proteins, and formulation.
- Remilk newsroom Official archive listing regulatory, product, financing, and facility announcements.
- Lab-made milk set to start pouring into Israeli dairy aisles, cafes Reputable reporting on the late-2025 Gad Dairies launch, product scope, locations, approvals, and company-reported investment and technology claims.
- Gad Dairies and Remilk present cow-free milk Reports the Israeli food-service launch and planned consumer rollout of The New Milk.
- Remilk LinkedIn company profile Company-reported founding year, employee range, private-company status, and Rehovot-area headquarters listing.
- Remilk raises $120 million in Series B funding Official financing announcement supporting late-stage private-company classification.
- Profile update timestamp Last updated in the Claw & Talon database on Jul 31, 2026.
Related sector
See the AI & Data Platforms sector page for market context, related subcategories, and other Israeli companies in this part of the database.